Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,995,416
  • Shares Outstanding, K 2,479,430
  • Annual Sales, $ 38,904 M
  • Annual Income, $ 1,974 M
  • 36-Month Beta 0.84
  • Price/Sales 2.55
  • Price/Cash Flow 10.42
  • Price/Book 22.05

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.85 +10.30%
on 03/26/18
41.08 -1.07%
on 04/10/18
+3.22 (+8.61%)
since 03/23/18
3-Month
34.89 +16.48%
on 02/06/18
41.08 -1.07%
on 04/10/18
+1.99 (+5.15%)
since 01/24/18
52-Week
34.52 +17.73%
on 12/06/17
44.53 -8.74%
on 05/31/17
-0.48 (-1.17%)
since 04/24/17

Most Recent Stories

More News
Global CNS Market Analysis 2018 With AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson & Pfizer Leading the Market - ResearchAndMarkets.com

The "Analyzing the Global CNS Market 2018" report has been added to ResearchAndMarkets.com's offering.

JNJ : 126.19 (-0.50%)
LLY : 80.09 (-0.14%)
GSK : 40.64 (+0.77%)
What's in the Cards for Glaxo (GSK) This Earnings Season?

Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

MRK : 60.09 (-0.27%)
NVS : 76.99 (-0.79%)
PFE : 37.06 (+0.71%)
GSK : 40.64 (+0.77%)
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1

Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.

ONCE : 75.38 (-3.27%)
NVS : 76.99 (-0.79%)
GSK : 40.64 (+0.77%)
AVXS : 210.60 (+0.32%)
Sanofi to Divest European Generic Unit, Streamline Business

Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

NVS : 76.99 (-0.79%)
SHPG : 163.93 (+2.41%)
GSK : 40.64 (+0.77%)
SNY : 39.75 (-0.50%)
NeuroMetrix Reports Q1 2018 Financial Results

NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended March 31, 2018.

NURO : 1.41 (-2.76%)
GSK : 40.64 (+0.77%)
Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting

- Preclinical testing raises no safety concerns for MAGE A4 -

ADAP : 12.22 (-0.57%)
GSK : 40.64 (+0.77%)
Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program....

MRK : 60.09 (-0.27%)
NVS : 76.99 (-0.79%)
ABBV : 91.36 (-1.94%)
PCRX : 35.30 (-0.28%)
PFE : 37.06 (+0.71%)
GSK : 40.64 (+0.77%)
BMY : 51.58 (+1.34%)
Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why

Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.

LGND : 161.77 (-3.26%)
NVS : 76.99 (-0.79%)
RIGL : 3.73 (+3.61%)
GSK : 40.64 (+0.77%)
Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?

The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

JNJ : 126.19 (-0.50%)
MRK : 60.09 (-0.27%)
ABBV : 91.36 (-1.94%)
GSK : 40.64 (+0.77%)
Glaxo to Sell Rare Disease Gene Therapies to Private Biotech

Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.

KHC : 56.53 (-1.99%)
NVS : 76.99 (-0.79%)
PFE : 37.06 (+0.71%)
GSK : 40.64 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

2nd Resistance Point 41.21
1st Resistance Point 40.93
Last Price 40.64
1st Support Level 40.36
2nd Support Level 40.07

See More

52-Week High 44.53
Fibonacci 61.8% 40.71
Last Price 40.64
Fibonacci 50% 39.53
Fibonacci 38.2% 38.34
52-Week Low 34.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar